Infinity Pharmaceuticals, Inc. & MedImmune, Inc. Start Phase 2 Clinical Trial of IPI-504 in Patients With Advanced Hormone-Refractory Prostate Cancer (PrimeNewsWire, 13 November 2007)

14 Nov 2007

Infinity Pharmaceuticals, Inc. and MedImmune, Inc. have announced that they have started a Phase 2 clinical trial of IPI-504, their lead heat shock protein 90 inhibitor, in patients with advanced hormone-refractory prostate cancer.